Antiangiogenic agents combined with systemic chemotherapy in refractory osteosarcoma
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference10 articles.
1. Lenvatinib with ifosfamide plus etoposide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, phase 1/2 study;Gaspar;Lancet Oncol,2021
2. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up;Casali;Ann Oncol,2018
3. Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: learning from the past to move forward;Lagmay;J Clin Oncol,2016
4. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study;Duffaud;Lancet Oncol,2019
5. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma;Davis;J Clin Oncol,2019
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Single-cell and spatial transcriptomics reveal metastasis mechanism and microenvironment remodeling of lymph node in osteosarcoma;BMC Medicine;2024-05-17
2. Ginger extract loaded Fe2O3/MgO‐doped hydroxyapatite: Evaluation of biological properties for bone–tissue engineering;Journal of the American Ceramic Society;2023-12-08
3. Multifunctional polydopamine – Zn2+-curcumin coated additively manufactured ceramic bone grafts with enhanced biological properties;Biomaterials Advances;2023-10
4. Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment;Frontiers in Oncology;2023-06-08
5. ZCCHC12 promotes the progression of osteosarcoma via PI3K/AKT pathway;Aging;2022-09-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3